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Current Metallodrugs in Cancer 
 
Metals occupy an important role in oncology, exemplified by platinum complexes, outlined 
in Chapters 9.3.4 and 21.2.3.2 of An Introduction to Medicinal Chemistry, 4th Edition. The 
low spectrum of cancers that can be treated, the side effects e.g. nephrotoxicity (kidney 
toxicity) and tumour resistance to these drugs have necessitated the search for newer, more 
effective drugs. Many platinum agents have been assessed with a relatively small degree of 
success and a number of alternative metal prototype drugs have been investigated with the 
goal of circumventing many of the shortcomings of cis-platin and its congeners. A small 
selection of investigational “metallodrugs” is presented below and subdivided according to 
the metal. 
 
Gallium 
Gallium (III) compounds, such as gallium nitrate, are being evaluated for the treatment of 
cancer, including hypercalcaemia (large levels of serum calcium associated with several late 
stage cancers). Many gallium compounds are thought to interfere with iron metabolism since 
Ga(III) and Fe(III) are chemically very similar. A current compound KP46 is illustrated, 
whereby an organic ligand, in this case, quinolin-8-ol, has been used to lower the toxicity and 
improve the bioavailability characteristics of Ga(III) (Fig. 1). 
 
Figure 1. KP46, an anticancer drug. 
 
Gold 
Traditionally, gold complexes have found uses in the treatment of rheumatoid arthritis. 
Recently, gold complexes have been investigated as anticancer agents, some due to their 
inhibition of the enzyme thioredoxin reductase (TrxR), which is involved in tumour growth. 
Recent Au complexes are illustrated in Figure 2. 
Patrick: An Introduction to Medicinal Chemistry, 4e 
OXFORD H i g h e r   E d u c a t i o n 
© Oxford University Press, 2009. All rights reserved. 
 
N
O
O
N
S
Au
Et3P
AuEt3P Cl Au
N
NN
N
+
N N
NN
Ph
Ph
Ph
Ph
Au
Cl
gold (III) porphyrin 1a  
Figure 2. Anticancer gold complexes. 
 
Palladium 
Palladium, being above platinum in the Periodic Table, has also been evaluated for anticancer 
activity although the cis-platin like complex cis-[Pd(NH3)2Cl2] is known to isomerise and 
rapidly hydrolyse, rendering it unsuitable for anticancer evaluation, since it is unstable in 
vivo and is consumed (creating toxicity and side effects) before reaching the target. A few 
recent palladium complexes with anticancer activity are known to inhibit cathepsin B (catB), 
an intracellular cysteine protease involved in tumour growth. The compounds in question are 
known as palladacycles. 
 
Figure 3. Palladacycle catB inhibitors. 
 
Ruthenium 
The cisplatin-like [RuCl3(NH3)3] was an early ruthenium complex evaluated for anticancer 
activity although its poor solubility led to the search for more suitable candidates. Indeed, a 
number of ruthenium prodrugs are now showing promising activity in clinical trials. They are 
able to enter cancer cells via a transferrin receptor (usually used for iron transport and 
upregulated in “iron” hungry cancer cells) due to the similarity of Ru to Fe. Once inside the 
cell, the hypoxic conditions (low oxygen levels) lead to reduction of Ru(III) to Ru(II). 
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NAMI-A and KP1019 have excellent antimetastatic action and the former exhibits relatively 
low cytotoxicity. Both are in clinical trials, showing promising results. 
 
Figure 4. Ruthenium anticancer agents in clinical trials. 
 
Given the likelihood of the lower oxidation state being the bioactive form of such complexes 
against cancer cells, a number of groups have directly synthesised Ru(II) analogues, which 
show good anticancer activity. 
 
Figure 5. Ru(II) anticancer agents. 
 
Titanium 
Titanocene dichloride was evaluated for anticancer activity due to its similarity to cis-platin 
but it was found to only weakly interact with DNA and was not successful due to its water 
instability. Its interactions with DNA were not as anticipated since it binds mainly to the 
phosphate backbone. 
 
Figure 6. Titanocene dichloride. 
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New generation metal complexes 
Recent anticancer agents with biological action have been designed whereby the high 
coordination number achievable in metal complexes (>4 compared with carbon) and the 
shape of the metal complexes can be put to use. Ferrocene resembles a three dimensional 
phenyl group and hydroxyferrocifen (a ferrocene based analogue of a metabolite of 
tamoxifen) was shown to have excellent anticancer action against breast cancer cell lines. To 
put these results into perspective, a ferrocene analogue of chloroquine (ferroquine) has 
progressed through clinical trials for the treatment of malaria, demonstrating that such 
metallodrugs are not merely academic curiosities. 
 
 
 
Figure 7. Ferrocene metallodrugs 
 
Meggers has coined the phrase “hypervalent carbon” in the use of metal complexes such as 
those of ruthenium. Many complexes have a hexacoordinate metal centre and allow the 
substituents to take up positions, and interact with enzymes or proteins, that are unachievable 
in traditional four coordinate carbon based organic chemistry (in Fig. 8, the metal scaffold 
replaces the sugar unit in staurosporine (see Figure 21.56 in book)). Consequently, these 
complexes are being used as highly selective chemical probes for elucidating the crystal 
structures of a number of biologically important kinases and proteins in cancer as the 
presence of a metal, and its high electron density, not only aids the refinement of the crystal 
structure but aids in stabilising the protein through binding. 
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Figure 8. Ruthenium analogues related to staurosporine.  
 
Conclusion 
The selected examples above highlight some recent developments in bioinorganic chemistry 
and emphasise the significance of coordination and organometallic chemistry (molecules with 
a metal carbon bond) in the development of potential new anticancer agents. In many 
instances, DNA is not the principle target of these new metallodrugs; enzymes such as 
cathepsin B or reductases expressed in cancer cells and later stage cancers are emerging as 
important targets. Finally, metal complexes are being used as chemical probes for proteins 
involved in a range of diseases and may pave the way to the design of new drugs by 
providing structural information on the binding sites of such proteins to be exploited by 
molecular modelling. 
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